Thomas A. Werfel

Thomas A. Werfel

Auto-generated profile, based on publicly available information

Thomas A. Werfel

Department of Biomedical Engineering, University of Mississippi, University, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2024 in ACS Nano
Verified
Journal Article
Closed access
KHKenneth Hulugalla
Kenneth Hulugalla
OSOluwaseyi Shofolawe-Bakare
Oluwaseyi Shofolawe-Bakare
VTVeeresh B. Toragall
Veeresh B. Toragall
SMSk Arif Mohammad
Sk Arif Mohammad
RMRailey Mayatt
Railey Mayatt
TWThomas Werfel
Thomas Werfel

1 April 2022 in Nanoscale
Verified
Journal Article
Closed access
PDF file
CHChristine M. Hamadani
Christine M. Hamadani
ICIndika Chandrasiri
Indika Chandrasiri
MYMahesh Loku Yaddehige
Mahesh Loku Yaddehige
GDGaya S. Dasanayake
Gaya S. Dasanayake
IOIyanuoluwani Owolabi
Iyanuoluwani Owolabi
ETEden E. L. Tanner
Eden E. L. Tanner
Linear-dendritic block copolymers (LDBCs) have emerged as promising materials for drug delivery applications, with their hybrid structure exploiting advantageous properties of both linear and dendritic polymers. LDBCs have promising encapsulation efficiencies that can be used to encapsulate both hydrophobic and hydrophilic dyes for bioimaging, cancer therapeutics, and small biomolecules. Additionally, LDBCS can be readily functionalized with varying terminal groups for more efficient targeted delivery. However, depending on structural composition and surface properties, LDBCs also exhibit high dispersities (Đ), poor shelf-life, and potentially high cytotoxicity to non-target interfacing blood cells during intravenous drug delivery. Here, we show that choline carboxylic acid-based ionic liquids (ILs) electrostatically solvate LDBCs by direct dissolution and form stable and biocompatible IL-integrated LDBC nano-assemblies. These nano-assemblies are endowed with red blood cell-hitchhiking capabilities and show altered cellular uptake behavior ex vivo. When modified with choline and trans-2-hexenoic acid, IL-LDBC dispersity dropped by half compared to bare LDBCs, and showed a significant shift of the cationic surface charge towards neutrality. Proton nuclear magnetic resonance spectroscopy evidenced twice the total amount of IL on the LDBCs relative to an established IL-linear PLGA platform. Transmission electron microscopy suggested the formation of a nanoparticle surface coating, which acted as a protective agent against RBC hemolysis, reducing hemolysis from 73% (LDBC) to 25% (IL-LDBC). However, dramatically different uptake behavior of IL-LDBCs vs. IL-PLGA NPs in RAW 264.7 macrophage cells suggests a different conformational IL-NP surface assembly on the linear versus the linear-dendritic nanoparticles. These results suggest that by controlling the physical chemistry of polymer-IL interactions and assembly on the nanoscale, biological function can be tailored toward the development of more effective and more precisely targeted therapies.

15 April 2023 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
PBParker R. Brewster
Parker R. Brewster
SBSaif Mohammad Ishraq Bari
Saif Mohammad Ishraq Bari
GWGlenn M. Walker
Glenn M. Walker
TWThomas A. Werfel
Thomas A. Werfel

18 January 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
DADhanush Amarasekara
Dhanush Amarasekara
CKChathuri S. Kariyawasam
Chathuri S. Kariyawasam
MHMadison A. Hejny
Madison A. Hejny
VTVeeresh B. Torgall
Veeresh B. Torgall
TWThomas A. Werfel
Thomas A. Werfel
NFNicholas C Fitzkee
Nicholas C Fitzkee

24 August 2020 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
OSOluwaseyi T. Shofolawe-Bakare
Oluwaseyi T. Shofolawe-Bakare
LSLarry D. Stokes
Larry D. Stokes
MHMehjabeen Hossain
Mehjabeen Hossain
ASAdam E. Smith
Adam E. Smith
TWThomas A. Werfel
Thomas A. Werfel
Cancer immunotherapy is exhibiting great promise as a new therapeutic modality for cancer treatment. However, immunotherapies are limited by the inability of some tumors to provoke an immune response. These tumors with a ‘cold’ immunological phenotype are characterized by low numbers of tumor-infiltrating lymphocytes, high numbers of immunosuppressive leukocytes (e.g. regulatory T cells, tumor-associated macrophages), and high production of immune-dampening signals (e.g. IL-10, TGF-β, IDO-1). Strategies to boost the aptitude of tumors to initiate an immune response (i.e. boost tumor immunogenicity) will turn ‘cold’ tumors ‘hot’ and augment the anti-tumor efficacy of current immunotherapies. Approaches to boost tumor immunogenicity already show promise; however, multifaceted delivery and immunobiology challenges exist. For instance, systemic delivery of many immune-stimulating agents causes off-target toxicity and/or the development of autoimmunity, limiting the administrable dose below the threshold needed to achieve efficacy. Moreover, once administered in vivo, molecules such as the nucleic acid-based agonists for many pattern recognition receptors are either rapidly cleared or degraded, and don't efficiently traffic to the intracellular compartments where the receptors are located. Thus, these nucleic acid-based drugs are ineffective without a delivery system. Biomaterials-based approaches aim to enhance current strategies to boost tumor immunogenicity, enable novel strategies, and spare dose-limiting toxicities. Here, we review recent progress to improve cancer immunotherapies by boosting immunogenicity within tumors using immunostimulatory biomaterials.

14 November 2022 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
JMJudith De Mel
Judith De Mel
MHMehjabeen Hossain
Mehjabeen Hossain
OSOluwaseyi Shofolawe-Bakare
Oluwaseyi Shofolawe-Bakare
SMSk Arif Mohammad
Sk Arif Mohammad
EREmily Rasmussen
Emily Rasmussen
TWThomas A. Werfel
Thomas A. Werfel